title: Immunogenicity of β-cells for autologous transplantation in type 1 diabetes.
abstract: The success of clinical islet transplantation calls for a broader application of this curative treatment for type 1 diabetes mellitus. The toxicity of immunosuppression, limited organ donor supply and high procedural costs are deterrents to expand this therapy to patients with uncomplicated diabetes. The use of pancreatic β-cell like cells derived from the patient's own induced pluripotent cells (iPSC) holds potential to overcome these barriers. In this review, we discuss the practicality of this regenerative medicine approach and existing evidence regarding the true immunogenicity of iPSC derived cells.
authors: Islet Transplantation Laboratory, Division of Transplantation, Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Thier 825, Boston, MA 02114, United States. Electronic address: chriscgn@gmail.com.
authors: Christian
authors: C
authors: Schuetz
authors: Islet Transplantation Laboratory, Division of Transplantation, Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Thier 825, Boston, MA 02114, United States.
authors: James F
authors: JF
authors: Markmann
mesh_terms: D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery* / Q000628:therapy; D006801:Humans; D050417:Insulin-Secreting Cells / Q000276:immunology* / Q000637:transplantation*; D016381:Islets of Langerhans Transplantation; D039904:Pluripotent Stem Cells / Q000637:transplantation; D014182:Transplantation, Autologous
keywords: Immune tolerance; Immunogenicity; Induced pluripotent stem cells; Islet transplantation; Pancreatic beta cells; Type 1 diabetes mellitus